Harnessing the Potential of Real-World Evidence in the Treatment of Colorectal Cancer: Where Do We Stand?
Authors:
- Sietske C. M. W. van NassauSNSietske C. M. W. van Nassau
- Guus M. BolGBGuus M. Bol
- Frederieke H. van der BaanFBFrederieke H. van der Baan
- Jeanine M. L. RoodhartJRJeanine M. L. Roodhart
- Geraldine R. VinkGVGeraldine R. Vink
- Cornelis J. A. PuntCPCornelis J. A. Punt
- Anne M. MayAMAnne M. May
- Miriam KoopmanMKMiriam Koopman
- Jeroen W. G. DerksenJDJeroen W. G. Derksen
Open Access
- 17 February 2024
- journal article
- review article
- Published by Springer Nature in Current Treatment Options in Oncology
- Vol. 25 (4) , 405-426
Abstract
Opinion statement: Treatment guidelines for colorectal cancer (CRC) are primarily based on the results of randomized clinical trials (RCTs), the gold standard methodology to evaluate safety and efficacy of oncological treatments. However, generalizability of trial results is often limited due to stringent eligibility criteria, underrepresentation of specific populations, and more heterogeneity in clinical practice. This may result in an efficacy-effectiveness gap and uncertainty regarding meaningful benefit versus treatment harm. Meanwhile, conduct of traditional RCTs has become increasingly challenging due to identification of a growing number of (small) molecular subtypes. These challenges—combined with the digitalization of health records—have led to growing interest in use of real-world data (RWD) to complement evidence from RCTs. RWD is used to evaluate epidemiological trends, quality of care, treatment effectiveness, long-term (rare) safety, and quality of life (QoL) measures. In addition, RWD is increasingly considered in decision-making by clinicians, regulators, and payers. In this narrative review, we elaborate on these applications in CRC, and provide illustrative examples. As long as the quality of RWD is safeguarded, ongoing developments, such as common data models, federated learning, and predictive modelling, will further unfold its potential. First, whenever possible, we recommend conducting pragmatic trials, such as registry-based RCTs, to optimize generalizability and answer clinical questions that are not addressed in registrational trials. Second, we argue that marketing approval should be conditional for patients who would have been ineligible for the registrational trial, awaiting planned (non) randomized evaluation of outcomes in the real world. Third, high-quality effectiveness results should be incorporated in treatment guidelines to aid in patient counseling. We believe that a coordinated effort from all stakeholders is essential to improve the quality of RWD, create a learning healthcare system with optimal use of trials and real-world evidence (RWE), and ultimately ensure personalized care for every CRC patient.Keywords
This publication has 110 references indexed in Scilit:
- Comparison of treatment outcome in metastatic colorectal cancer patients included in a clinical trial versus daily practice in The NetherlandsActa Oncologica, 2013
- Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo-controlled, phase 3 trialThe Lancet, 2013
- Comparative Effectiveness Research in Oncology Methodology: Observational DataJournal of Clinical Oncology, 2012
- Using scenarios to explain life expectancy in advanced cancer: attitudes of people with a cancer experienceSupportive Care in Cancer, 2012
- Adherence to Stage-Specific Treatment Guidelines for Patients With Colon CancerJournal of Clinical Oncology, 2012
- Framework for the impact analysis and implementation of Clinical Prediction Rules (CPRs)BMC Medical Informatics and Decision Making, 2011
- Rethinking pragmatic randomised controlled trials: introducing the "cohort multiple randomised controlled trial" designBMJ, 2010
- Good Research Practices for Comparative Effectiveness Research: Approaches to Mitigate Bias and Confounding in the Design of Nonrandomized Studies of Treatment Effects Using Secondary Data Sources: The International Society for Pharmacoeconomics and Outcomes Research Good Research Practices for Retrospective Database Analysis Task Force Report—Part IIValue in Health, 2009
- External validity of randomised controlled trials: “To whom do the results of this trial apply?”The Lancet, 2005
- The Will Rogers PhenomenonNew England Journal of Medicine, 1985